Feedback / Questions
ESK-001 - Alumis
https://www.globenewswire.com/news-release/2024/09/27/2954511/0/en/Late-Breaking-Data-at-EADV-of-ESK-001-an-Oral-TYK2-Inhibitor-for-the-Treatment-of-Psoriasis-Demonstrate-Significant-Responses-with-Sustained-Increases-Over-28-Weeks-in-Phase-2-OLE-.html
Sep 27, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next